1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Aeterna Zentaris Inc.

Aeterna Zentaris Inc.

AEZS.TO
Aeterna Zentaris Inc.CA flagToronto Stock Exchange
8.29
CAD
+0.62
- -
25.38MMarket Cap
Aeterna Zentaris Inc.
AEZS.TO
(Toronto Stock Exchange)

Recent

price

8.29

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
3.13
3.57
4.44
4.25
3.65
4.31
5.33
5.27
6.37
5.78
4.73
5.41
6.48
7.36
7.54
3.93
3.91
Revenue per Share
-2.66
-0.06
0.37
0.42
-0.38
0.12
0.96
2.43
1.69
-0.43
-0.13
-0.48
0.79
1.44
1.76
-1.92
-2.66
Basic EPS, GAAP
-1.05
-0.83
0.31
0.49
-0.26
-1.2
-1.49
-0.11
-0.04
-1.09
-1.38
0.23
1.64
1.2
2.5
-1.88
-3.17
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-5.42
-6.03
-5.43
0.09
-4.76
-4.33
-2.98
-0.03
1.71
8.17
7.64
7.42
8.41
9.86
11.04
9.34
11.94
Book Value per Share
-1.45
-1.14
-0.54
0.35
-0.04
0.12
1.23
3.87
10.42
9.75
9.47
9.37
10.4
11.85
12.93
11.36
11.61
Tangible Book Value per Share
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
Basic Weighted Avg Shares
3
4
6
6
5
6
8
8
10
10
9
10
12
13
14
7
8
Sales/Revenue/Turnover
-28.99
4.91
7.06
13.23
-7.78
8.79
24.61
36.34
45.65
4.95
8.36
-2.53
15.52
19.21
29.19
-64.93
-114.42
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
1
Depreciation Expense
-3
- -
- -
1
-1
- -
1
4
3
-1
- -
-1
1
3
3
-4
-5
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
32.51
- -
- -
- -
- -
- -
23.87
- -
- -
Effective Tax Rate (%)
-85.13
-1.59
8.32
9.98
-10.42
2.69
17.93
46.14
26.47
-7.41
-2.72
-8.79
12.27
19.57
23.34
-48.89
-67.98
Profit Margin (%)
-2
-1
-1
- -
- -
1
-1
-1
7
4
4
4
6
9
14
10
23
Working Capital
1
2
1
1
1
2
2
2
1
- -
- -
2
2
2
2
1
1
LT Debt
-2
-1
-1
1
- -
- -
2
6
17
18
17
17
19
22
24
21
26
Total Equity
- -
- -
- -
57.57
- -
26.46
47.61
- -
22.8
- -
- -
- -
8.98
- -
12.45
- -
- -
Return on Invested Capital (%)
- -
- -
- -
-37.65
- -
-4.87
-62.74
- -
69.8
- -
- -
- -
9.44
- -
15.63
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-8.83
-1.64
-6.36
10.07
15.78
16.88
-18.9
-24.26
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
2
3
Market Capitalization
19
22
12

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
11
9
33
Cash, Cash Equivalents & STI
7
4
28
Accounts Receivable, Net
- -
1
1
Inventories
4
4
3
Total Current Liabilities
1
1
10
Payables & Accruals
1
1
5
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
111.96%
4.71%
-11.74%
Free Cash Flow
294%
82.5%
-175.38%
Net Income, GAAP
56.88%
-19.81%
-209.56%
Sales/Revenue/Turnover
4.66%
1.02%
-47.69%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
5
4
3
3
14
2023
3
1
2
1
7
2024
2
2
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
0.79
0.76
0.4
- -
1.76
2023
-0.15
-0.47
-0.41
- -
-1.92
2024
-0.76
-0.64
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Reunion Neuroscience Inc. (REUN.TO)
Scancell Holdings plc (SCNLF)
Immutep Limited (IMMP)
Jounce Therapeutics, Inc. (JNCE)
Abcam plc (ABCM)
AnGes, Inc. (4563.T)
Business
COSCIENS Biopharma Inc. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc. Aeterna Zentaris Inc., operates as a specialty biopharmaceutical company focused on developing and commercializing innovative therapeutics, diagnostic products, and active ingredients derived from renewable plant resources for the healthcare, cosmeceutical, and nutraceutical industries. The company offers macimorelin (marketed as Macrilen in the U.S. and Ghryvelin in Europe), the first and only FDA- and European Commission-approved oral diagnostic test for adult growth hormone deficiency; proprietary natural extracts including oat beta glucan for skin moisture barrier replenishment, wound healing, cholesterol reduction, blood sugar control, and gut health; oat avenanthramides to soothe skin irritation, reduce redness, and combat inflammation linked to exercise, heart disease, diabetes, and arthritis in liquid and powder forms; and oat oil rich in antioxidants, vitamin E, essential fatty acids, and emollients for skin barrier repair, hydration, and use in cosmetics and hair products. COSCIENS targets endocrinology, oncology, and women's health segments with peptide- and small-molecule-based technologies, serving pharmaceutical partners, healthcare providers, and consumer brands such as Aveeno and Burt’s Bees across global markets including North America and Europe. Founded in 1990 and headquartered in Quebec City, Quebec, Canada, with prior offices in Charleston, South Carolina, and Frankfurt, Germany, the company maintains operations through wholly owned subsidiaries like Aeterna Zentaris GmbH. In recent developments, COSCIENS completed an all-stock merger of equals with Ceapro Inc. in June 2024 to diversify into plant-based active ingredients and revenue streams from cosmeceuticals and nutraceuticals; changed its name from Aeterna Zentaris Inc. to COSCIENS Biopharma Inc. effective August 6, 2024, with trading symbol shifting to CSCI on NASDAQ and TSX as of August 9, 2024; and continues to advance therapeutic assets in oncology and endocrinology while optimizing commercialization partnerships for macimorelin.